Vivus News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.01.19	5 Top Gainers In Healthcare Sector (MBOT, VVUS, RNN...) (RTTNews)
02.05.18	AKAO On Watch, SCYX To Report Data In July, FDA Panel Nod For SIGA (RTTNews)
01.09.17	Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS (PR Newswire)
31.08.17	AMGN's Endeavor Awaits Verdict, NVS Scripts History, OTIC Is Not Music To Ears (RTTNews)
31.08.17	VIVUS Settles With Dr. Reddy's Labs On Qsymia Patent Litigation (RTTNews)
28.08.17	Developments in the Erectile Dysfunction Markets (PR Newswire)
06.07.17	ARRY Working Its Way, Be All Ears For Auris, BGNE Inks Deal With CELG (RTTNews)
30.06.17	Biotech Stock Performance Review -- Vertex Pharma, VIVUS, Xbiotech, and Axovant Sciences (PR Newswire)
15.05.17	How These Biotech Stocks are Faring? -- Seattle Genetics, Sangamo Therapeutics, Vertex Pharma, and VIVUS (PR Newswire)
27.03.17	VIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi - Quick Facts (RTTNews)
17.03.17	Research Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx Pharma, Cymabay Therapeutics, and Omeros (PR Newswire)
10.03.17	Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM... (RTTNews)
24.01.17	On the Beauty Trend Radar 2017: Eyebrow Restoration (PR Newswire)
18.01.17	Research Reports Coverage on Biotech Stocks -- Emergent BioSolutions, Chimerix, VIVUS, and RXi Pharma (PR Newswire)
04.10.16	DVAX Back In News, Spectral Shock For Investors, MACK Giving Pink Slips (RTTNews)
16.04.15	Celsion Warms Up, AMGN Gets FDA Nod, SKBI Put On Notice, VVUS Sues Teva (RTTNews)
16.04.15	VIVUS Files Lawsuit Against Teva For Infringement Of Qsymia Patents (RTTNews)
26.11.14	Vivus Gets Two Additional U.S. Patents For Qsymia - Quick Facts (RTTNews)
06.11.14	ADMA To Be Uplisted, VVUS Up After-Hours, NVAX For The Long Haul, CCXI On Watch (RTTNews)
18.09.14	Vivus And Auxilium Pharma Say FDA Approves SNDA For Stendra - Quick Facts (RTTNews)
26.08.14	ADXS Makes It Big, ALKS Waiting To Face FDA, ITMN Snapped Up, KITE Flies High (RTTNews)
25.08.14	VIVUS Announces Acquisition Of Group Of Patents From Janssen Pharma (RTTNews)
25.03.14	AcelRx Pharma Names Timothy Morris CFO - Quick Facts (RTTNews)
12.02.14	New Weight-loss Drugs Look Like Slim Pickings, Say Dartmouth Researchers (RTTNews)
13.12.13	CRMD Awaits Makeover, INSY In Crosshairs, Plandaí On A High, SNTA Enchants (RTTNews)
13.11.13	VIVUS Reports Issuance Of 2 Key US Patents For Qsymia - Quick Facts (RTTNews)
16.10.13	Pre-Market Review: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc. (PR Newswire)
16.10.13	Successful Launches, Upcoming Conference Calls, Signing of Agreements, and Trial Results - Research Report on Vertex, Illumina, Alexion, VIVUS, and Endocyte (PR Newswire)
09.10.13	VIVUS Announces New Data Demonstrating Effects Of Qsymia Capsules CIV (RTTNews)
07.10.13	Changes in Senior Management, Grants of Orphan Drug Designations, and Updates on Pipeline Development and NDA - Research Report on Vivus, Omeros, Delcath Systems, Achillion, and Zogenix (PR Newswire)
17.09.13	Technical Study: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc. (PR Newswire)
03.09.13	Vivus Names Seth Fischer CEO, As Anthony Zook Resigns Due To Ill Health (RTTNews)
03.09.13	Biotech Firms Announce Financial Results, Resignations, Reintroduce Treatments and Receive Reviews on Key Products - Research Report on Insmed, ImmunoGen, VIVUS, Theravance, and XOMA (PR Newswire)
03.09.13	Vivus Names Seth Fischer CEO, Succeeding Anthony Zook - Quick Facts (RTTNews)
09.08.13	Technical Scrutiny: Vivus Inc., Sanofi, DENTSPLY Intl., and Acura Pharma (PR Newswire)
09.08.13	Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS (PR Newswire)
07.08.13	Vivus Q2 Loss Widens As Qsymia Sales Miss Estimates, Shares Drop 3% (RTTNews)
06.08.13	Vivus Q2 Loss Widens - Quick Facts (RTTNews)
25.07.13	Results Schedules, Management Changes, and Pending NDA Approvals - Research Report on Questcor, VIVUS, Exelixis, Incyte, and Chelsea Therapeutics (PR Newswire)
23.07.13	Vivus Names AstraZeneca Executive Anthony Nook As CEO After Proxy Settlement (RTTNews)
23.07.13	VIVUS Names Michael Astrue Chairman & Anthony Zook CEO, Effective Today (RTTNews)
19.07.13	Vivus Reaches Settlement With First Manhattan; Anthony Zook To Be Named New CEO (RTTNews)
17.07.13	Vivus: First Manhattan Rejects Compromise Offer - Quick Facts (RTTNews)
16.07.13	First Manhattan Files Litigation Against Vivus For Delaying Stockholders Meeting (RTTNews)
15.07.13	First Manhattan Issues Statement On Vivus' Adjourning Stockholders Meeting (RTTNews)
14.07.13	Vivus Invites 3 FMC Nominees To Join Board - Quick Facts (RTTNews)
09.07.13	Vivus Urges Shareholders To Re-elect Current Board - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’293.50	1.97 %	K V
ABB	50.04	1.13 %	K V
Holcim	89.00	1.04 %	K V
Roche Hldg G	266.60	0.83 %	K V
UBS Group	29.61	0.58 %	K V
Givaudan	3’884.00	-0.49 %	K V
Zurich Insur Gr	547.20	-0.83 %	K V
Geberit	508.20	-1.05 %	K V
Sonova Hldg	294.80	-1.07 %	K V
Logitech Intl	78.84	-1.30 %	K V

mehr

07.01.25		Dienstagshandel in New York: Dow Jones letztendlich in der Verlustzone
07.01.25		EURO STOXX 50-Titel Sanofi-Aktie: So viel Gewinn hätte eine Investition in Sanofi von vor einem Jahr abgeworfen
02.01.25		Börse New York in Grün: S&P 500 zum Start im Plus
31.12.24		Schwacher Handel: NASDAQ 100 beendet die Sitzung im Minus
31.12.24		Dienstagshandel in New York: NASDAQ 100 leichter
31.12.24		Wie Experten die Sanofi-Aktie im Dezember einstuften
31.12.24		EURO STOXX 50-Wert Sanofi-Aktie: So viel Gewinn hätte eine Sanofi-Investition von vor 10 Jahren eingebracht
27.12.24		Schwache Performance in New York: S&P 500 fällt zum Handelsende zurück

07.01.25

Dienstagshandel in New York: Dow Jones letztendlich in der Verlustzone

07.01.25

EURO STOXX 50-Titel Sanofi-Aktie: So viel Gewinn hätte eine Investition in Sanofi von vor einem Jahr abgeworfen

02.01.25

Börse New York in Grün: S&P 500 zum Start im Plus

31.12.24

Schwacher Handel: NASDAQ 100 beendet die Sitzung im Minus

31.12.24

Dienstagshandel in New York: NASDAQ 100 leichter

31.12.24

Wie Experten die Sanofi-Aktie im Dezember einstuften